Epigenomics and AstraZeneca form pact:
This article was originally published in Clinica
Executive Summary
Bolstering its efforts in the field of personalised medicine, Epigenomics has teamed up with AstraZeneca to discover biomarkers that may form part of AstraZeneca's strategy for targeting drugs at the patients most likely to respond to them. Berlin, Germany-based Epigenomics will use its proprietary technology to identify DNA methylation markers from clinical tumour samples embedded in paraffin for use in AstraZeneca's cancer drug discovery and development programme. The programme will initially focus on AstraZeneca's selective epidermal growth factor receptor tyrosine kinase inhibitor, Iressa.